Colorectal cancer is one of the most common malignancies and the second leading cause of death from cancer in the western world, representing one million new cases and half a million deaths annually worldwide. Since the mid-1980s, both the incidence and mortality rates of colorectal cancer have decreased, due at least in part to increased rates of screening and polyp removal.
The median duration of OS, the primary end-point of this study, was 20.3 months for those in the BEV group and 15.6 months in the placebo group (p<001) (see Figure 1) .
One-year survival rates were 74.3 and 63.4% for those who received IFL plus BEV and IFL plus placebo, respectively. Secondary end-points were a 10.6-month PFS (IFL plus BEV) compared with a 6.2-month PFS (IFL plus placebo) (see Figure 2 ).
BEV also has activity in the second-line setting but not in the third-line Median survival times in patients treated with FOLFOX plus BEV were 12.5 months versus 10.7 months for patients treated with FOLFOX alone. 5 By way of first-line treatment, the randomised trial Three Regimens of Eloxatin Evaluation (TREE-2) compared three oxaliplatin-based regimens with or without the addition of BEV. Recently reported results showed an Colorectal Cancer overall response rate (RR) in patients randomised to receive FOLFOX plus BEV versus FOLFOX alone of 52 and 41%, respectively. This study was also important in that it demonstrated that capecitabine could be combined successfully with oxaliplatin and BEV in American patients, resulting in a 48% RR and a 10.3-month median time to progression. 6 On the other hand, an international phase III trial (NO16966) was initiated to estimate the efficacy of capcitabine and oxaliplatin (XELOX) and and September 2005 were included. Pre-specified characteristics of tumour burden, age, severe toxicity and front-line regimen efficacy were analysed. Eighty-seven patients treated with the specified front-line regimens were selected. Seventy-six per cent of the eligible patients were treated with a second cytotoxic agent. In spite of equal therapy durations, patients with a better response of stable disease were significantly less likely to receive a third-line regimen than patients with a partial response (68 versus 95%, odds ratio 8.2; p=0.02) due to declining performance status (86%) or patient preference (14%). This was in correlation with a decreased two-year OS (86 versus 55%). Tumour burden, age and development of toxicity were not associated with a different utilisation of a second-line regimen. Therefore, failure to obtain a response to initial chemotherapy for MCRC results is to be connected with decreased utilisation of the second-line regimen. 8 In conclusion, BEV is currently approved for the first-line treatment of MCRC combined with 5-FU-based chemotherapy and is currently being tested in combination with standard therapies for a range of indications. In fact, the addition of BEV to fluoropyrimidine chemotherapy, with or without irinotecan or oxaliplatin, in both the first-and second-line treatment of MCRC improved median PFS by 4.7 months and 2.1 months, respectively. The tolerability of BEV is acceptable. Common adverse events are hypertension, rash, fever, headache, thrombotic events, proteinuria and haemorrhage. Incidence of any serious adverse events occurred with low frequency. Only severe hypertension was significantly higher with BEV than with the placebo patients. In the EU, the dosage for therapy of MCRC is 5mg/kg once every two weeks administered as an intravenous infusion. Treatment should be continued until progression.
Cetuximab -Mechanism of Action and Clinical Efficacy
The EGFR is a member of the ErbB group of receptors. It is composed of extracellular domains, including a ligand-binding region, 
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The RR in the combination therapy group (arm A) was significantly higher than that in the monotherapy group (arm B) (22.9 versus 10.8%; p=0.007). The median time to progression was also significantly greater in the combination therapy group (4.1 versus 1.5 months; p<0.001). No survival benefit for arm A was observed over arm B. Nevertheless, CET was demonstrated to have clinically significant activity when given alone or in combination with irinotecan, and it consequently received US Food and Drug Administration (FDA) approval for use in patients whose disease is refractory to irinotecan with tumours expressing EGFR. 10 VEGF and EGFR have different mechanisms of action. The feasibility of administering BEV and CET in combination was addressed in the BOND-2 study. All patients had not been treated previously with CET or BEV.
Patients in arm A received irinotecan at the same dose and schedule as last given prior to study entry, plus CET 400mg/m 2 loading dose, then weekly CET 250mg/m 2 plus BEV 5mg/kg administered every other week.
Patients in arm B received the same CET and BEV as those in arm A but without irinotecan.
Forty-three patients received CET, BEV and irinotecan (CBI) and 40
patients received CET and BEV alone (CB). For the CBI arm, time to tumour progression (TTP) was 7.3 months and the RR was 37%; for the CB arm, TTP was 4.9 months and the RR was 20% (see Figure 3) . The OS for the CBI arm was 14.5 months and the OS for the CB alone arm was 11.4 months (see Figure 4 ). In conclusion, CET and BEV can be administered concurrently with a toxicity that seems to be identical to that which would be expected from the two drugs alone. This combination plus irinotecan also seems to be feasible. The action seen with the addition of BEV to CET, or to CET plus irinotecan, seems to be advantageous in this setting. Combination of biologicals is feasible, but financial considerations constitute a problem. 11 The CAIRO2 study is another randomised phase III trial on capecitabine, treatment of MCRC has to be assessed in phase III trials. 13 All studies show that CET can increase OS in patients with refractory MCRC and that CET has encouraging activity in second-line treatment.
Promising action has also been evaluated in first-line treatment in combination with FOLFIRI and FOLFOX, but new clinical studies are needed to determine the combination and sequence of these drugs.
CET is generally well tolerated. Dermatological toxicity (acne-form rash)
is the most frequent problem associated with CET. The rash typically appears on the face, neck and chest. The intensity of the acne-form rash seems to be correlated to drug activity. Infusion reaction (hypotension, airway obstruction and cardiac arrest) may occur during first-line treatment with CET and requires immediate interruption of the infusion. In addition, the dosage for therapy is 400mg/m 2 initially, followed by 250mg/m 2 weekly.
Conclusions
Randomised studies have shown that survival or time to TTP of MCRC is improved when BEV is used in combination with cytotoxic drugs (5-FU with or without irinotecan or oxaliplatin). CET was approved for therapy on the basis of a large, randomised phase II study, but its therapeutic contribution in MCRC needs to be clarified. According to recommendations on the use of molecular-targeted agents in combination with chemotherapy for MCRC, BEV should be considered in first-line treatment of patients with a good performance status and CET in third-line treatment.
More recent studies estimate promising CET action in second-line treatment after oxaliplatin-based therapy failure and with first-line chemotherapy, where increased RRs seen with adding cetuximab to first-line therapy for MCRC may increase the chances for curative surgery in a population for whom the treatment would otherwise be palliative. 14 ■
